pentetate calcium trisodium (Rx)Brand and Other Names:Ca-DTPA

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable/inhalation solution

  • 1g/5mL
more...

Internal Contamination

Contamination with plutonium, americium, or curium radionuclides

  • 1 g slow IV push over 3-4 minutes OR
  • IV infusion (in 100-250 mL D5W or LR or NS) OR
  • Inhalation in a nebulizer (1:1 with water or saline)
  • IV administration should not be protracted over >2 hours
  • Can be administered undiluted by IM (off-label) if IV is not practical; coadministration of 1-2% procaine may alleviate injection site pain
  • After initial decontamination, generally switched over to the less potent but less toxic Zn-DTPA if necessary
  • Repeat doses may be adminnistered up to 5 days/week qDay
  • Full decontamination may require prolonged treatment

Other Indications & Uses

Ca-DTPA is 10 times more effective than Zn-DTPA

Dosage Forms & Strengths

injectable/inhalation solution

  • 1g/5mL
more...

Internal Contamination

<12 years old: 14 mg/kg IV qDay initially; not to exceed >1 g/day

Maintenance: 14 mg/kg/day IV; not to exceed 1 g/day

>12 years old: As in adults

Next

Adverse Effects

(Repeated administration over a short period)

Frequency Not Defined

Anosmia

Chills

Fever

Muscle cramps

Nausea

Pruritus

Vomiting

Chest pain

Dermatitis

Diarrhea

Metallic taste

Trace element deficiency

Depletion of zinc, magnesium, manganese and metalloproteinase (during prolonged treatment)

Previous
Next

Warnings

Nephrotic synd/preexisting serious kidney dz

Bone marrow depression (eg, leukopenia, thrombocytopenia)

Not for uranium or neptunium

Obtain written consent for tx

Severe hemachromatosis

Do not divide dose

May lead to depletion of endogenous trace metals

Discontinue if diarrhea occurs

Monitor BP during infusion

Previous
Next

Pregnancy & Lactation

Pregnancy Category: C

Lactation: N/A

Pregnancy Categories

A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA:Information not available.

more...
Previous
Next

Pharmacology

Distribution: In extracellular fluid, very little in cells/tissues

Metabolism: minimal

Excretion: predominantly in urine, almost completely in 12 hr; feces <3%

Ca-DTPA (Akorn, Inc, call 1-800-932-5676; [inj/inh soln]: 1 g/5 mL vial)

Mechanism of Action

Chelates transuranium metals

Previous
Next

Images

Previous
Next

Formulary

FormularyPatient Discounts

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Add or Remove Plans
Plans for
Select State:
Non-Medicare PlansMedicare Plans

Select a box to add or remove a plan.

Select a class to view formulary status for similar drugs

Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.